KOSDAQ - Delayed Quote KRW

FutureChem Co.,Ltd (220100.KQ)

Compare
24,650.00 +500.00 (+2.07%)
At close: October 4 at 3:30 PM GMT+9
Loading Chart for 220100.KQ
DELL
  • Previous Close 24,150.00
  • Open 0.00
  • Bid --
  • Ask --
  • Day's Range 0.00 - 0.00
  • 52 Week Range 0.00 - 28,000.00
  • Volume 0
  • Avg. Volume 1,037,205
  • Market Cap (intraday) 544.689B
  • Beta (5Y Monthly) 1.20
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

FutureChem Co.,Ltd produces and sells radiopharmaceuticals in Korea. The company offers PDVUE, a positron emission tomography (PET) radiopharmaceutical diagnostic medicine for Parkinson's disease; Alzavue, a diagnostic medicine for Aalzheimer's disease; and [18F]FDG, a PET radiopharmaceutical for the treatment of cancer. Its products in pipeline include 18F-FC303, a diagnostic PET radiopharmaceuticals for the treatment of prostate cancer; 177Lu-FC705 for the treatment of prostate cancer; 18F-FMT for the treatment of brain tumor; 18F-FC505, for the treatment of atherosclerotic plaque; and 18F-FC211, for the treatment of Alzheimer's disease. FutureChem Co.,Ltd was founded in 1999 and is headquartered in Seoul, South Korea.

www.futurechem.co.kr

67

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 220100.KQ

View More

Performance Overview: 220100.KQ

Trailing total returns as of 10/4/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

220100.KQ
133.65%
KOSPI Composite Index
3.22%

1-Year Return

220100.KQ
89.62%
KOSPI Composite Index
6.82%

3-Year Return

220100.KQ
89.62%
KOSPI Composite Index
14.89%

5-Year Return

220100.KQ
205.19%
KOSPI Composite Index
27.17%

Compare To: 220100.KQ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 220100.KQ

View More

Valuation Measures

Annual
As of 10/4/2024
  • Market Cap

    544.69B

  • Enterprise Value

    524.35B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    36.50

  • Price/Book (mrq)

    9.32

  • Enterprise Value/Revenue

    35.15

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -58.49%

  • Return on Assets (ttm)

    -7.70%

  • Return on Equity (ttm)

    -13.91%

  • Revenue (ttm)

    14.92B

  • Net Income Avi to Common (ttm)

    -8.73B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    23.54B

  • Total Debt/Equity (mrq)

    5.46%

  • Levered Free Cash Flow (ttm)

    -2.28B

Research Analysis: 220100.KQ

View More

Company Insights: 220100.KQ

Research Reports: 220100.KQ

View More

People Also Watch